NIH awards $2.47M grant to University of Maryland medical school for E. Coli vaccine development

Baltimore-based University of Maryland School of Medicine received $2.47 million from the National Institutes of Health to develop a vaccine against Shigella and Enterotoxigenic E. Coli, which is a leading cause of diarrheal disease in young children in developing countries.

Advertisement

The three-year grant was awarded to university principal investigators Eileen M. Barry, PhD, professor of medicine, and Wilbur H Chen, MD, associate professor of medicine. The researchers already tested a prototype of the vaccine in animals. The grant was awarded to develop this into an efficacious human vaccine.

“Nearly half a million children die each year of diarrheal diseases, and Shigella and ETEC infections are a common cause,” Dr. Barry said. “This grant will help us translate our research into a vaccine ready for human trials.”

More articles on healthcare finance:
9 recent hospital, health system outlook and credit rating actions
12 hospitals seeking RCM talent
Hyundai Hope on Wheels to expand pediatric cancer research grants

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.